J&J Eprex Sales Stabilize As Aplasia Cases Decline; Patient Registry Planned

Johnson & Johnson is focusing on rebuilding Eprex now that quarterly sales have stabilized for the first time since a labeling revision regarding pure red cell aplasia in chronic renal failure patients